KPW
IOVA icon

Kore Private Wealth’s Iovance Biotherapeutics IOVA Stock Holding History

Kore Private Wealth’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$13K – 661
2020
Q2 		$13K Hold
500
– – ﹤0.01% 737
2020
Q1 		$15K Hold
500
– – ﹤0.01% 628
2019
Q4 		$14K Buy
+500
New +$11.4K ﹤0.01% 693
2019
Q2 		– Sell
-1,000
Closed -$10K – 508
2019
Q1 		$10K Buy
+1,000
New +$9.71K ﹤0.01% 625

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Kore Private Wealth's IOVA Position: Q3 2020 in Review

Kore Private Wealth sold out of Iovance Biotherapeutics (IOVA) in Q3 2020, closing a stake of 500 shares — an estimated $13K sold.

Kore Private Wealth first reported a position in IOVA in Q1 2019 and held it in 4 quarters. The position peaked at $15K in Q1 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q3 2020.

  • Kore Private Wealth reported no remaining Iovance Biotherapeutics position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 500 Iovance Biotherapeutics shares in Q3 2020, an estimated $13K.
  • Kore Private Wealth first reported a position in Iovance Biotherapeutics in Q1 2019 and held it in 4 quarters.
  • Kore Private Wealth's Iovance Biotherapeutics position peaked at $15K in Q1 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.